|

Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease

RECRUITINGSponsored by Metcela Inc.
Actively Recruiting
SponsorMetcela Inc.
Started2026-09-01
Est. completion2030-02-28
Eligibility
Healthy vol.Accepted

Summary

The objective of this observational study is to investigate the long-term safety of autologous cardiac stem cells (JRM-001) administered to patients with single ventricle physiology. This study will conduct a one-year safety follow-up of participants in "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease".

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients who participated in "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease" and meet the following criteria;
* JRM-001 administration group: received JRM-001 investigational product after catheter examination
* Non-administered group: underwent cardiac catheter examiniation only

Exclusion Criteria:

* Patients who is difficult to visit the clinical trial site
* Patients who is difficult to obtain the provision of medical information from clinical institute to which the patient is transferred

Conditions3

Heart DiseaseHypoplastic Left Heart Syndrome (HLHS)Single-ventricle

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.